EP1179344B1 - Freisetzungsregulierende zubereitungen - Google Patents

Freisetzungsregulierende zubereitungen Download PDF

Info

Publication number
EP1179344B1
EP1179344B1 EP00900919A EP00900919A EP1179344B1 EP 1179344 B1 EP1179344 B1 EP 1179344B1 EP 00900919 A EP00900919 A EP 00900919A EP 00900919 A EP00900919 A EP 00900919A EP 1179344 B1 EP1179344 B1 EP 1179344B1
Authority
EP
European Patent Office
Prior art keywords
group
atom
compound
reaction
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP00900919A
Other languages
English (en)
French (fr)
Other versions
EP1179344A4 (de
EP1179344A1 (de
Inventor
Kiyoyuki Teijin Limited SAKON
Yoshiaki Teijin Limited IGARASHI
Masahiko Teijin Limited NARASAKI
Kentaro Teijin Limited FUJINAGA
Yoji Teijin Limited YAMAMOTO
Hiroaki Teijin Limited MITSUHASHI
Kazuoki Teijin Limited TSURUTA
Hirofumi Teijin Limited TANABE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd filed Critical Teijin Ltd
Publication of EP1179344A1 publication Critical patent/EP1179344A1/de
Publication of EP1179344A4 publication Critical patent/EP1179344A4/de
Application granted granted Critical
Publication of EP1179344B1 publication Critical patent/EP1179344B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to medicinal compositions effective for improving the absorption of a compound of formula (I) through digestive tracts by reducing the contact of the compound with components of bile or pancreatic juice secreted in the duodenum.
  • Medicinal compositions added with cyclodextrins and lipophilic substances such as medium-chain fatty acid triglycerides were disclosed in the specifications of the JP-A 9-2977 (hereinafter, JP-A means "Japanese Unexamined Patent Application”.) and JP-A 10-231254 as the compositions to improve the absorption of aromatic amidine derivatives through the digestive tracts.
  • JP-A means "Japanese Unexamined Patent Application”.
  • JP-A 10-231254 as the compositions to improve the absorption of aromatic amidine derivatives through the digestive tracts.
  • the long-term safety of cyclodextrins administered by peroral administration is not sufficiently confirmed and the lipophilic substance such as medium-chain triglyceride is possible to cause the adverse effects on the digestive tracts such as diarrhea and the risk of the failure in the barrierness of the digestive tract membrane.
  • WO 98/3202 disclosed a medicinal composition containing an anion exchange resin with respect to aromatic amidine derivatives.
  • cholestyramine shown as a preferable example of anion exchange resin in the specification is the active component itself used as a medicine for hyperlipemia and the substance is not expectable as a preferable material from the safety point of view owing to its new physiological action.
  • the object of the present invention is to provide medicinal compositions containing the compound of formula (I) effective for improving the absorption through the digestive tracts by reducing the contact of the compound with the components in the bile or pancreatic juice in the case of peroral administration.
  • the present invention provides medicinal compositions containing one or more compounds selected from the compounds represented by the following formula (I), salts of these compounds, solvates of these compounds and solvates of these salts (hereinafter collectively called as "the compounds of the present invention” in some cases) and wherein the medicinal composition is coated with an enteric polymer resistant to dissolution below pH 4.5 and soluble at pH 4.5 or above and being capable of reducing the contact of the compounds with the components in the bile or pancreatic juice, wherein said enteric polymer is one or more kinds selected from the group consisting of hydroxypropylmethyl cellulose acetate succinate, hydroxypropylmethyl cellulose phthalate, carboxymethyl ethylcellulose, cellulose acetate phthalate, cellulose acetate, trimellitate, polyvinyl acetate phthalate and methacrylic acid copolymer wherein R 1 is hydrogen atom, fluorine atom, chlorine atom, bromine atom, hydroxyl group, amino group, nitro group, a C
  • the "C 1 -C 8 alkyl group” means a straight or branched carbon chain having 1 to 8 carbon atoms, for example, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, tert-butyl group, pentyl group, neopentyl group, isopentyl group, 1,2-dimethylpropyl group, hexyl group, isohexyl group, 1,1-dimethylbutyl group, 2,2-dimethylbutyl group, 1-ethylbutyl group, 2-ethylbutyl group, isoheptyl group, octyl group or isooctyl group, preferably a group having a carbon number of from 1 to 4, especially preferably methyl group or ethyl group.
  • the "C 1 -C 8 alkoxy group” means an alkoxy group having a carbon number of from 1 to 8, concretely methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, pentyloxy group, neopentyloxy group, tert-pentyloxy group, 2-methylbutoxy group, hexyloxy group, isohexyloxy group, heptyloxy group, isoheptyloxy group, octyloxy group, isooctyloxy group, preferably a group having a carbon number of from 1 to 4, especially preferably methoxy group or ethoxy group.
  • C 1 -C 4 alkylene means a straight-chain alkylene having a carbon number of from 1 to 4 and is methylene, ethylene, propylene or butylene.
  • C 1 -C 8 alkoxycarbonyl group means methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, isopropoxycarbonyl group, butoxycarbonyl group, isobutoxycarbonyl group, sec-butoxycarbonyl group, tert-butoxycarbonyl group, pentyloxycarbonyl group, isopentyloxycarbonyl group, neopentyloxycarbonyl group, hexyloxycarbonyl group, heptyloxycarbonyl group, octyloxycarbonyl group, preferably methoxycarbonyl group, ethoxycarbonyl group or tert-butoxycarbonyl group, more preferably methoxycarbonyl group.
  • aryloxycarbonyl group means phenoxycarbonyl group, naphthyloxycarbonyl group, 4-methylphenoxycarbonyl group, 3-chlorophenoxycarbonyl group, 4-methoxyphenoxycarbonyl group, preferably phenoxycarbonyl group.
  • the "aralkoxycarbonyl group” means benzyloxycarbonyl group, 4-methoxybenzyloxycarbonyl group, 3-trifluoromethylbenzyloxycarbonyl group, preferably benzyloxycarbonyl group.
  • amino acid means natural or non-natural commercially available amino acids, preferably glycine, alanine or ⁇ -alanine, more preferably glycine.
  • C 1 -C 8 alkylcarbonyl group means a carbonyl group having straight or branched carbon chain having a carbon number of from 1 to 8, e.g. formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, pivaloyl group, hexanoyl group, heptanoyl group and octanoyl group, preferably a carbonyl group having a carbon number of from 1 to 4, more preferably acetyl group or propionyl group.
  • C 1 -C 8 alkylsulfenyl group means an alkylsulfenyl group having a carbon number of from 1 to 8, concretely methylthio group, ethylthio group, butylthio group, isobutylthio group, pentylthio group, hexylthio group, heptylthio group, octylthio group, preferably methylthio group.
  • C 1 -C 8 alkylsulfinyl group means an alkylsulfinyl group having a carbon number of from 1 to 8, concretely methylsulfinyl group, ethylsulfinyl group, butylsulfinyl group, hexylsulfinyl group, octylsulfinyl groups preferably methylsulfinyl group.
  • C 1 -C 8 alkylsulfonyl group means an alkylsulfonyl group having a carbon number of from 1 to 8, concretely methylsulfonyl group, ethylsulfonyl group, butylsulfonyl group, hexylsulfonyl group, octylsulfonyl group preferably methylsulfonyl group.
  • the "mono- or di-C 1 -C 8 alkylamino group” means methylamino group, dimethylamino group, ethylamino group, propylamino group, diethylamino group, isopropylamino group, diisopropylamino group, dibutylamino group, butylamino group, isobutylamino group, sec-butylamino group, tert-butylamino group, pentylamino group, hexylamino group, heptylamino group, octylamino group, preferably methylamino group, dimethylamino group, ethylamino group, diethylamino group or propylamino group, more preferably methylamino group or dimethylamino group.
  • the "mono- or di-C 1 -C 8 alkylaminosulfonyl group” means methylaminosulfonyl group, dimethylaminosulfonyl group, ethylaminosulfonyl group, propylaminosulfonyl group, diethylaminosulfonyl group, isopropylaminosulfonyl group, diisopropylaminosulfonyl group, dibutylaminosulfonyl group, butylaminosulfonyl group, isobutylaminosulfonyl group, sec-butylaminosulfonyl group, tert-butylaminosulfonyl group, pentylaminosulfonyl group, hexylaminosulfonyl group, heptylaminosulfonyl group, octylaminosulfonyl group, preferably methylaminosulfonyl group
  • bis(alkoxycarbonyl)methyl group means bis(methoxycarbonyl)methyl group, bis(ethoxycarbonyl)methyl group, preferably bis(methoxycarbonyl)methyl group.
  • C 1 -C 10 alkyl group means a straight or branched carbon chain having a carbon number of from 1 to 10, e.g. methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, tert-butyl group, pentyl group, neopentyl group, isopentyl group, 1,2-dimethylpropyl group, hexyl group, isohexyl group, 1,1-dimethylbutyl group, 2,2-dimethylbutyl group, 1-ethylbutyl group, 2-ethylbutyl group, heptyl group, isoheptyl group, 1-methylhexyl group, 2-methylhexyl group, octyl group, 2-ethylhexyl group, nonyl group, decyl group, 1-methylnonyl group, preferably a group having a carbon number of from 1 to 4, especially
  • C 1 -C 10 alkylcarbonyl group means a carbonyl group having straight or branched carbon chain having a carbon number of from 1 to 10, e.g. formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, pivaloyl group, hexanoyl group, heptanoyl group, octanoyl group, nonanoyl group, decanoyl group, preferably a group having a carbon number of from 1 to 4, more preferably acetyl group or propionyl group.
  • C 1 -C 10 alkylsulfonyl group means an alkylsulfonyl group having a carbon number of from 1 to 10, concretely methylsulfonyl group, ethylsulfonyl group, propylsulfonyl group, isopropylsulfonyl group, butylsulfonyl group, isobutylsulfonyl group, pentylsulfonyl group, isopentylsulfonyl group, neopentylsulfonyl group, hexylsulfonyl group, heptylsulfonyl group, octylsulfonyl group, nonylsulfonyl group, decylsulfonyl group, preferably a group having a carbon number of from 1 to 4, especially preferably methylsulfonyl group or ethylsulfonyl group
  • C 3 -C 8 cycloalkyl group means a cycloalkyl group having a carbon number of from 3 to 8, concretely cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group and cyclooctyl group, preferably cyclopropyl group.
  • aryl group means a hydrocarbon ring aryl group such as phenyl group and naphthyl group or a heteroaryl group such as pyridyl group and furyl group, preferably phenyl group.
  • C 4 -C 8 cycloalkyl group means a cycloalkyl group having a carbon number of from 4 to 8, concretely cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group or cyclooctyl group, preferably cyclopentyl group or cyclohexyl group.
  • aminoalkyl group means a straight-chain alkyl group having a carbon number of from 1 to 8, concretely 8-aminooctyl group, 6-aminohexyl group, 4-aminobutyl group, 2-aminoethyl group or aminomethyl group, preferably 2-aminoethyl group or aminomethyl group.
  • the "mono- or di-alkylamino group” means methylamino group, dimethylamino group, ethylamino group, propylamino group, diethylamino group, isopropylamino group, diisopropylamino group, dibutylamino group, butylamino group, isobutylamino group, sec-butylamino group, tert-butylamino group, preferably methylamino group, dimethylamino group, ethylamino group, diethylamino group, isopropylamino group or diisopropylamino group, more preferably ethylamino group, diethylamino group or isopropylamino group.
  • the "mono- or di-alkylaminoalkyl group” means methylaminoethyl group, dimethylaminoethyl group, ethylaminoethyl group, methylaminopropyl group, dimethylaminopropyl group, ethylaminopropyl group, diethylaminopropyl group, methylaminobutyl group, dimethylaminobutyl group, etc., preferably methylaminoethyl group, dimethylaminoethyl group or ethylaminoethyl group.
  • the "C 1 -C 10 alkyl group” bonding to a nitrogen atom as the group Z means a straight or branched carbon chain having a carbon number of from 1 to 10, e.g. methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, tert-butyl group, pentyl group, neopentyl group, isopentyl group, 1,2-dimethylpropyl group, hexyl group, isohexyl group, 1,1-dimethylbutyl group, 2,2-dimethylbutyl group, 1-ethylbutyl group, 2-ethylbutyl group, heptyl group, isoheptyl group, 1-methylhexyl group, 2-methylhexyl group, octyl group, 2-ethylhexyl group, nonyl group, decyl group, 1-methylnonyl group preferably a
  • arylcarbonyl group means benzoyl group, 4-methoxybenzoyl group, 3-trifluoromethylbenzoyl group, preferably benzoyl group.
  • the "aralkylcarbonyl group” is concretely benzylcarbonyl group, phenethylcarbonyl group, phenylpropylcarbonyl group, 1-naphthylmethylcarbonyl group, 2-naphthylmethylcarbonyl group, preferably benzylcarbonyl group.
  • the "aralkyl group” is concretely benzyl group, phenethyl group, phenylpropyl group, 1-naphthylmethyl group, 2-naphthylmethyl group, preferably benzyl group.
  • the salt of the compound of the present invention there is no particular restriction on the kind of the salt of the compound of the present invention provided that the salt is pharmacologically permissible, and the examples of the salts are hydrochloric acid salt, sulfuric acid salt, nitric acid salt, phosphoric acid salt, tartaric acid salt, maleic acid salt, succinic acid salt, malonic acid salt, glutaric acid salt, malic acid salt, adipic acid salt, acetic acid salt, propionic acid salt, hydrobromic acid salt, hydroiodic acid salt, methanesulfonic acid salt, 2-hydroxysulfonic acid salt and p-toluenesulfonic acid salt.
  • the etherification reaction is carried out preferably after properly protecting such functional groups and the protecting group is eliminated after the reaction.
  • Any protecting group ordinarily used for the protection of individual substituent can be used as the protecting group provided that the substituent exerts no adverse influence on the other part of the molecule during the protecting and deprotecting steps.
  • the protecting groups for hydroxyl group are trialkylsilyl group, C 1 -C 4 alkoxymethyl group, tetrahydropyranyl group, acyl group, C 1 -C 4 alkoxycarbonyl group, etc.
  • the protecting groups for amino group are C 1 -C 4 alkoxycarbonyl group, benzyloxycarbonyl group, acyl group, etc.
  • the protecting groups for carboxyl group are C 1 -C 4 alkyl group, etc.
  • the deprotection reaction can be performed according to a process usually adopted to the protecting group.
  • the compounds containing oxygen atom as the group X among the nitrile compound used as a precursor of the compound of the present invention expressed by the formula (I) can be synthesized e.g. by the reaction shown by the following reaction formula (a-1).
  • reaction formula (a-1) the definitions of R 1 , R 3 , L, m and n are same as those described in the formula (I)
  • Y 1 is a substituent Y defined in the formula (I) except for the group having a substituent Z of the structure expressed by the formula I-3 on the group Y
  • R 8 is hydrogen atom, fluorine atom, chlorine atom, bromine atom, hydroxyl group (or its protected group), amino group (or its protected group) or C 1 -C 8 alkoxy group.
  • a nitrile compound as a precursor of the compound of the present invention can be produced according to the above reaction formula (a-1) by mixing a biphenylalkyl bromide compound used as a starting raw material with an alcohol of formula Y 1 -(CH 2 ) n -OH in the presence of a base.
  • the compound containing oxygen atom as the group X among the nitrile compounds used as the precursor of the compound of the present invention expressed by the formula (I) can be synthesized by the reaction expressed by the following reaction formula (a-2). [in the reaction formula, the definitions of R 1 , R 3 , L, m and n are same as those of the formula (I), and Y 1 is a substituent Y defined in the formula (I) except for the group having a substituent Z of the structure expressed by the formula I-3 on the group Y].
  • the nitrile compound used as a precursor of the compound of the present invention can be synthesized by mixing 3-bromo-3-iodophenylalkyl bromide used as a starting raw material with an alcohol expressed by the formula Y 1 -(CH 2 ) n -OH in the presence of a base to form a 3-bromo-3-iodophenylalkyl ether compound, introducing a substituent -L-COOMe into the obtained ether compound by monocarbonylation or monoalkylation and subjecting the produced 3-bromophenylalkyl ether to coupling reaction with a cyanophenylboronic acid derivative.
  • the etherification reaction expressed in the 1st stage of the reaction formulas (a-1) and (a-2) is carried out by using an aliphatic ether such as tetrahydrofuran and diethyl ether, an aprotic hydrocarbon such as benzene and toluene, an aprotic polar solvent such as DMF and HMPA or their mixture.
  • the base to be used in the reaction is a metal oxide such as barium oxide and zinc oxide, a metal hydroxide such as sodium hydroxide and potassium hydroxide, metal hydride such as sodium hydride, etc.
  • the reaction proceeds usually by stirring at 0 to 100°C for 3 to 72 hours.
  • the reaction is carried out in an anhydrous aliphatic ether such as THF and ether using sodium hydride at 20 to 80°C for 8 to 36 hours.
  • the 2nd stage of the reaction formula (a-2) comprising the reaction to introduce a substituent -L-COOMe into the ether compound can be carried out by the following reactions (i) and (ii).
  • the biphenylation reaction constituting the 3rd stage of the reaction formula (a-2) can be performed by reacting a monohalogenated compound with cyanophenyl boronic acid in the presence of a palladium catalyst.
  • the reaction proceeds usually by stirring the monohalogenated compound obtained by the 2nd stage of the reaction formula (a-2), a bivalent palladium catalyst such as palladium acetate and further a base such as triethylamine and a triaryl phosphine in DMF under heating to obtain the objective cyanobiphenyl compound.
  • the reaction is preferably carried out at 60 to 100°C for 2 to 24 hours.
  • the compound having nitrogen atom as the group X among the nitrile compounds constituting the precursor of the compound of the present invention described by the formula (I) can be synthesized e.g. by the reaction of the following reaction formula (b-1) or (b-2).
  • reaction formula the definitions of R 1 , R 3 , L, m and n are same as those described in the formula (I)
  • R 9 is fluorine atom, chlorine atom, bromine atom, hydroxyl group (or its protected group), amino group (or its protected group), a C 1 -C 8 alkoxy group or methoxycarbonyl group among the substituents R 2 defined in the formula (I)
  • Y 1 is a substituent Y defined in the formula (I) except for the group having a substituent Z of the structure expressed by the formula I-3 on the group Y
  • R 10 is the substituent R 4 defined in the formula (I) excluding hydrogen atom and aryl group
  • E is an eliminable group such as chlorine, bromine,
  • R 9 is fluorine atom, chlorine atom, bromine atom, hydroxyl group (or its protected group), amino group (or its protected group), a C 1 -C 8 alkoxy group or methoxycarbonyl group among the substituents R 2 defined in the formula (I)
  • Y 1 is a substituent Y defined in the formula (I) except for the group having a substituent Z of the structure expressed by the formula I-3 on the group Y
  • Ar is an aryl group
  • E is an eliminable group such as chlorine, bromine, iodine, acyloxy group or sulfonyloxy group].
  • the N-alkylation reaction shown by the reaction formulas (b-1) and (b-2) can be carried out under known alkylation reaction conditions.
  • a secondary amine compound constituting the compound of the present invention is produced by reacting a biphenylalkyl bromide used as a raw material with an amine of formula Y 1 -(CH 2 ) n -NH 2 in the presence of an inorganic salt such as potassium carbonate or an amine such as a tertiary amine acting as a base and the obtained secondary amine compound can be converted to the tertiary amine as the compound of the present invention by reacting with an alkylation agent expressed by the formula R 4 -E.
  • the reaction is usually carried out by mixing the alkylation agent and the amine at an arbitrary ratio in a proper solvent and by stirring the mixture under cooling, at room temperature or under heating for 1 to 96 hours.
  • the reaction is usually performed by using an inorganic salt such as potassium carbonate and sodium carbonate or an organic tertiary amine such as triethylamine and pyridine as the base and an alcohol such as methanol and ethanol, a hydrocarbon such as benzene and toluene, a solvent inert to the reaction such as THF, dioxane, acetonitrile DMF and DMSO or their mixture as the solvent at an (alkylation agent):(amine) ratio of 1:10 to 10:1.
  • the ratio of the alkylation agent to the amine is set to 1:5 to 1:1 and the reaction is carried out at room temperature or under heating for 2 to 24 hours.
  • the compound containing sulfur atom as the group X among the nitrile compounds constituting a precursor of the compound of the present invention expressed by the formula (I) can be synthesized e.g. by the reaction shown by the following reaction formula (c-1) or (c-2).
  • R 9 is fluorine atom, chlorine atom, bromine atom, hydroxyl group (or its protected group), amino group (or its protected group), a C 1 -C 8 alkoxy group or methoxycarbonyl group among the substituents R 2 defined in the formula (I)
  • Y 1 is a substituent Y defined in the formula (I) except for the group having a substituent Z of the structure expressed by the formula I-3 on the group Y
  • E is an eliminable group such as chlorine, bromine, iodine or sulfonato group.
  • R 9 is fluorine atom, chlorine atom, bromine atom, hydroxyl group (or its protected group), amino group (or its protected group), a C 1 -C 8 alkoxy group or methoxycarbonyl group among the substituents R 2 defined in the formula (I)
  • Y 1 is a substituent Y defined in the formula (I) except for the group having a substituent Z of the structure expressed by the formula I-3 on the group Y
  • E is an eliminable group such as chlorine, bromine, iodine or sulfonato group.
  • the thioetherification reaction expressed by the reaction formulas (c-1) and (c-2) can be carried out under known reaction conditions. Usually, the reaction is carried out by mixing an alkyl halide with a thiol at an arbitrary ratio in a proper solvent in the presence of a base such as sodium hydroxide or ammonia and stirring the mixture under cooling, at room temperature or under heating for 30 minutes to 96 hours. A solvent free from adverse effect on the reaction such as water, ethanol, DMF or toluene is used as the reaction solvent and the base is sodium hydroxide, ammonia, cesium carbonate, etc.
  • the reaction is preferably carried out by mixing the alkyl halide with the thiol at a ratio of 1:5 to 5:1 and stirring the mixture at room temperature or under heating for 30 minutes to 24 hours.
  • a compound having sulfoxide group or sulfone group as the group X among the compounds expressed by the formula (I) can be synthesized by the oxidation reaction of the obtained sulfide compound according to the following reaction formula (d).
  • reaction formula (d) the definitions of R 1 , R 3 , L, m and n are same as those described in the formula (I)
  • R 9 is fluorine atom, chlorine atom, bromine atom, hydroxyl group (or its protected group), amino group (or its protected group), a C 1 -C 8 alkoxy group or methoxycarbonyl group among the substituents R 2 defined in the formula (I)
  • Y 1 is a substituent Y defined in the formula (I) except for the group having a substituent Z of the structure expressed by the formula I-3 on the group Y].
  • the oxidation reaction expressed by the reaction formula (d) can be carried out by the method described in the Experimental Chemistry Course (4th edition), 24, Organic Syntheses VI - Hetero-Element. Typical Metal Compound-, p.350-373 edited by the Chemical Society of Japan.
  • the reaction is usually carried out by stirring a sulfide or a sulfoxide in water or an alcohol such as methanol using hydrogen peroxide, peracetic acid, meta-periodic acid salt, m-chloroperbenzoic acid, etc., as an oxidizing agent under cooling, at room temperature or under heating for 30 minutes to 24 hours.
  • the sulfoxide is produced at 0-20°C in 30 to 12 hours and the sulfone is produced at 0-80°C in 1 to 12 hours.
  • the compound containing amide bond as the group X among the nitrile compounds constituting a precursor of the compound of the present invention expressed by the formula (I) can be synthesized e.g. by the reaction shown by the following reaction formula (e-1) or (e-2).
  • R 9 is fluorine atom, chlorine atom, bromine atom, hydroxyl group (or its protected group), amino group (or its protected group), a C 1 -C 8 alkoxy group or methoxycarbonyl group among the substituents R2 defined in the formula (I)
  • Y 1 is a substituent Y defined in the formula (I) except for the group having a substituent Z of the structure expressed by the formula I-3 on the group Y
  • G is a group such as halogen, acyloxy group, p-nitrophenoxy group and hydroxyl group.
  • R 9 is fluorine atom, chlorine atom, bromine atom, hydroxyl group (or its protected group), amino group (or its protected group), a C 1 -C 8 alkoxy group or methoxycarbonyl group among the substituents R2 defined in the formula (I)
  • Y 1 is a substituent Y defined in the formula (I) except for the group having a substituent Z of the structure expressed by the formula I-3 on the group Y
  • G is a group such as halogen, acyloxy group, p-nitrophenoxy group and hydroxyl group.
  • the reaction of the above reaction formula (e-1) or (e-2) can be carried out under the known amidation reaction conditions.
  • An amide compound is produced usually by mixing an active derivative of a carboxylic acid with an amine compound in a proper solvent in the presence of a base, followed with acylating the compound.
  • the active derivative of carboxylic acid is an acid halide, an anhydride of a mixed acid, an active ester of p-nitrophenol, etc., and the reaction is carried out under cooling or at room temperature for 30 minutes to 24 hours.
  • the reaction is preferably carried out by using a tertiary amine such as triethylamine as the base in a halogenated hydrocarbon such as dichloromethane, an aliphatic ether such as THF and diethyl ether, a solvent such as acetonitrile and DMF or their mixture at 0 to 20°C for 1 to 18 hours.
  • a tertiary amine such as triethylamine
  • a halogenated hydrocarbon such as dichloromethane
  • an aliphatic ether such as THF and diethyl ether
  • a solvent such as acetonitrile and DMF or their mixture at 0 to 20°C for 1 to 18 hours.
  • the amide compound is producible also by the condensation reaction of an amine with a carboxylic acid in the presence of a condensing agent such as carbodiimide.
  • a condensing agent such as carbodiimide.
  • the suitable solvent is DMF and a halogenated hydrocarbon such as chloroform and the condensing agent is preferably N,N-dicyclohexylcarbodiimide, 1-ethyl-(3-(N,N-dimethylamino)propyl)carbodiimide, carbonyl diimidazole, diphenylphosphoryl azide or diethylphosphoryl cyanide.
  • the reaction is carried out usually under cooling or at room temperature for 2 to 48 hours.
  • the compound containing sulfonamide structure as the group X among the nitrile compounds constituting a precursor of the compound of the present invention expressed by the formula (I) can be synthesized e.g. by the reaction shown by the following reaction formula (f-1) or (f-2).
  • R 9 is fluorine atom, chlorine atom, bromine atom, hydroxyl group (or its protected group), amino group (or its protected group), a C 1 -C 8 alkoxy group or methoxycarbonyl group among the substituents R2 defined in the formula (I)
  • Y 1 is a substituent Y defined in the formula (I) except for the group having a substituent Z of the structure expressed by the formula I-3 on the group Y].
  • R 9 is fluorine atom, chlorine atom, bromine atom, hydroxyl group (or its protected group), amino group (or its protected group), a C 1 -C 8 alkoxy group or methoxycarbonyl group among the substituents R2 defined in the formula (I)
  • Y 1 is a substituent Y defined in the formula (I) except for the group having a substituent Z of the structure expressed by the formula I-3 on the group Y].
  • the reaction expressed by the reaction formulas (f-1) and (f-2) can be carried out by reacting an amine with an active derivative of a sulfonic acid in a proper solvent in the presence of a base to obtain the objective sulfonamide compound.
  • the active derivative of sulfonic acid is preferably a sulfonyl halide and the reaction is carried out by using a tertiary amine such as triethylamine as the base in a halogenated hydrocarbon such as dichloromethane, an aliphatic ether such as THF or diethyl ether, a solvent such as acetonitrile or DMF or their mixture at 0 to 20°C for 1 to 24 hours.
  • the compound containing urea structure as the group X among the nitrile compounds constituting a precursor of the compound of the present invention expressed by the formula (I) can be synthesized e.g. by the reaction shown by the following reaction formula (g).
  • reaction formula (g) the definitions of R 1 , R 3 , L, m and n are same as those described in the formula (I)
  • R 9 is fluorine atom, chlorine atom, bromine atom, hydroxyl group (or its protected group), amino group (or its protected group), a C 1 -C 8 alkoxy group or methoxycarbonyl group among the substituents R 2 defined in the formula (I)
  • Y 1 is a substituent Y defined in the formula (I) except for the group having a substituent Z of the structure expressed by the formula I-3 on the group Y].
  • the compound having urea structure as the group X can be produced by reacting an amine as a starting raw material with an isocyanate derivative in a proper solvent under cooling or heating.
  • the solvent to be used in the reaction is DMF, THF, dioxane, dichloroethane, chloroform, acetonitrile, DMSO, benzene, toluene, etc.
  • the nitrile compound constituting a precursor of the compound of the present invention and produced by the above reaction formulas (a-1), (a-2), (b-1), (b-2), (c-1), (c-2), (d), (e-1), (e-2), (f-1), (f-2) and (g) can be converted to a benzamidine derivative which is a compound of the present invention by the amidination reaction shown by the following reaction formula (h).
  • Y 1 is a substituent Y defined in the formula (I) except for the group having a substituent Z of the structure expressed by the formula I-3 on the group Y
  • R 9 is fluorine atom, chlorine atom, bromine atom, hydroxyl group (or its protected group), amino group (or its protected group), a C 1 -C 8 alkoxy group or methoxycarbonyl group among the substituents R 2 defined in the formula (I)
  • R 11 is a C 1 -C 4 alkyl group.
  • the compound having the substituent Y containing a substituent Z having the structure expressed by the formula I-3 among the compounds of the present invention expressed by the formula (I) can be produced by producing a benzamidine compound having a secondary amino group in the substituent Y by the reaction expressed by the above reaction formula (h), followed by the imidoylation reaction of the product according to the following reaction formula (j-1).
  • R 1 , R 3 , R 6 , L, W, X, Z, m and n are same as those described in the formula (I), and R 9 is fluorine atom, chlorine atom, bromine atom, hydroxyl group (or its protected group), amino group (or its protected group), a C 1 -C 8 alkoxy group or methoxycarbonyl group among the substituents R 2 defined in the formula (I)].
  • the imidoylation reaction proceeds by mixing and stirring a benzamidine compound having a secondary amino group in the substituent Y together with an equivalent or excess amount of an imidate in water, a C 1 -C 4 alcohol such as methanol or ethanol, an aliphatic ether such as diethyl ether, a halogenated hydrocarbon such as chloroform, a polar solvent such as DMF or DMSO or their mixture in the presence of a base.
  • the reaction is usually carried out for 1 to 24 hours at room temperature.
  • the base to be used in the above reaction is N-methylmorpholine, triethylamine, diisopropylethylamine, sodium hydroxide, potassium hydroxide, etc.
  • the compound having carboxyl group as the group R 2 among the compounds expressed by the formula (I) can be produced by the ester hydrolysis of a compound having methoxycarbonyl group as the group R 9 among the benzamidine compounds produced by the above reaction formulas (h) and (j-1).
  • the hydrolysis reaction can be carried out under basic condition, acidic condition or neutral condition at need.
  • the base to be used in the reaction under basic condition is sodium hydroxide, potassium hydroxide, lithium hydroxide, barium hydroxide, etc.
  • the acid for the acidic reaction condition is hydrochloric acid, sulfuric acid, a Lewis acid such as boron trichloride, trifluoroacetic acid, p-toluenesulfonic acid, etc.
  • the examples of the substances to be used in the reaction under neutral condition are halogen ions such as lithium iodide and lithium bromide, alkali metal salts of a thiol and selenol, iodotrimethylsilane and enzymes such as an esterase.
  • the solvent for the reaction is a polar solvent such as water, alcohol, acetone, dioxane, THF, DMF and DMSO or their mixture.
  • the reaction is carried out usually at room temperature or under heating for 2 to 96 hours.
  • the preferable conditions of the reaction temperature and reaction time, etc., are dependent on the reaction condition and properly selected according to conventional method.
  • the carboxyl group of the compound having carboxyl group as the substituent R 2 and produced by this process can be converted to other ester group by the following methods of (v), (vi) and (vii).
  • the carboxyl group of a compound having a carboxyl group as the R 2 group can be converted into carbamoyl group by conventional method such as the conversion of the carboxyl group to an acid halide with oxalyl chloride, etc., followed by the reaction of the product with ammonia water.
  • the acid halide can be converted to N-methyl-N-methoxycarbamoyl group by reacting with N-methyl-N-methoxyamine and the product can be converted further to an alkylcarbonyl group by the reaction with various kinds of alkylmagnesium reactants.
  • the compound expressed by the formula (I) can be produced also by an arbitrary combination of known processes usually adoptable by persons skilled in the art such as etherification, amidination, hydrolysis, alkylimidoylation, amidation and esterification.
  • the alkoxymethylphenylbenzamidine derivative I produced by the above method can be separated and purified by conventional methods such as extraction, precipitation, fractional chromatography, fractional crystallization and recrystallization.
  • the pharmacologically permissible salt of the compound of the present invention can be produced by the conventional salt-forming reaction.
  • the medicinal composition of the present invention is characterized by the property to reduce the contact of the compound of the present invention with components of bile or pancreatic juice secreted in the duodenum.
  • the reduction of the contact of the compound of the present invention with the components of bile or pancreatic juice means that the contact of the medicinal composition of the present invention with the components of bile or pancreatic juice is reduced compared with a composition usually taking a solution state in the stomach or a conventional oral administration drug quickly releasing the active component in the stomach.
  • composition of the present invention can avoid the suppression of the absorption of the compound by reducing the contact of the compound of the present invention with the components of the bile or pancreatic juice.
  • a release-site regulating preparation is a preferable embodiment of the medicinal composition of the present invention.
  • the medicinal composition can hold the compound in the medicinal composition at least down to the duodenum to prevent the diffusion of the compound in the digestive tract and release the compound when the medicinal composition reaches the duodenum or the following small intestine or large intestine by its physiological condition or by a preparatorily integrated time-dependent mechanism.
  • the medicinal composition are shown below.
  • a medicinal composition produced by coating the compound of the present invention with a pH-dependently soluble enteric polymer.
  • the medicinal composition (1) is produced by coating a constituent component containing the compound of the present invention with a pH-dependently soluble enteric polymer, i.e. an enteric polymer resistant to dissolution below pH 4.5 and soluble at pH 4.5 or above.
  • a pH-dependently soluble enteric polymer i.e. an enteric polymer resistant to dissolution below pH 4.5 and soluble at pH 4.5 or above.
  • the pH-dependent enteric polymer is, for example, anionic polymers such as hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, carboxymethyl ethylcellulose, cellulose acetate phthalate, cellulose acetate trimellitate, polyvinyl acetate phthalate and methacrylic acid copolymer.
  • anionic polymers such as hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, carboxymethyl ethylcellulose, cellulose acetate phthalate, cellulose acetate trimellitate, polyvinyl acetate phthalate and methacrylic acid copolymer.
  • the medicinal composition (2) is a composition containing the compound of the present invention and a disintegrant and partly or totally covered its surface with a layer composed of a water-insoluble and water-permeable substance.
  • the swelling of the disintegrant takes place by the water permeated through the layer to cause the collapse or burst of the medicinal composition after the lapse of a prescribed period.
  • the layer composed of the water-insoluble and water-permeable substance does not pass the compound.
  • the prescribed period means the time necessary to reach the medicinal composition to the duodenum having the opening of common bile duct to discharge the bile juice and pancreatic juice at high concentration or to pass the composition through the duodenum.
  • the period is especially dependent upon the time to discharge the composition from the stomach.
  • the discharging time from the stomach is considerably dependent upon the ingestion condition of food and the time of from several minutes to 24 hours is reported by a literature (Biopharmaceutics of Administered Drugs; P. Macheras, C. Reppas and J. B. Dressman; p89-p123; Ellis Horwood).
  • the prescribed period is specified to 0.5 to 4.5 hours taking consideration of the fact that the discharging period from the stomach is about 0.5 to 4.5 hours in the case of administering to an empty stomach or after a light meal.
  • Preferable examples of the water-insoluble and water-permeable substance are ethylcellulose and cellulose acetate.
  • the disintegrant is preferably e.g. cellulose, cellulose lower alkyl ether, starch or its derivative.
  • the medicinal composition (3) is a composition produced by coating the compound of the present invention with a material decomposable by enteric bacteria indigenous to the lower part of the small intestine to the large intestine and releases the compound at the lower part of the digestive tract by the decomposition of the coating material with the enteric bacteria.
  • the enteric bacteria mean bacteria indigenous mainly to the lower part of the small intestine to the large intestine.
  • the material to be decomposed by the enteric bacteria is preferably an azo-containing segmented polyurethane, chitosan, etc.
  • Each of the medicinal compositions (1), (2) and (3) may be incorporated with a base foamable by the generation of carbon dioxide gas when the environment reaches a prescribed physical condition or after the lapse of a prescribed period.
  • Preferable example of the base to generate carbon dioxide gas is a combination of sodium bicarbonate with citric acid, tartaric acid, fumaric acid or their salts.
  • the medicinal composition of the present invention may be further incorporated as necessary with a pharmacologically permissible excipient.
  • the administration rate of the compound of the present invention depends upon the kind of disease, administration method, symptom of the patient, age, sex, body weight, etc., and generally the rate is 1 to 1,000 mg/day/head, preferably 10 to 300 mg/day/head by oral administration.
  • Powder of the compound (A) was encapsulated together with an excipient in a hard capsule made of M-type hydroxypropylmethyl cellulose acetate succinate (HPMCAS) (AQOAT; product of Shin-Etsu Chemical Co., Ltd.) having pH dependency and dissolving in the intestines.
  • the capsules were administered to four fasted crab-eating monkeys of 5.5 to 7.0 kg body-weight at a rate of 5 mg/kg and about 2 mL each of blood was collected at 7 points, i.e. immediately before the administration of the compound (A) and 0.5, 1, 2, 4, 8 and 10 hours after the administration.
  • the plasma was separated and the concentration of the compound (A) was determined by LC/MS.
  • Example 1 Enteric capsule containing the compound (A)
  • a tablet containing 3-(3-amidinophenyl)-5-[(1-acetimidoyl-4-piperidinyl)methylaminomethyl]benzoic acid (hereinafter referred to as compound (A)) was prepared as a comparative example by the following method. Namely, 12.50 grams of the compound (A), 114.25 grams of lactose (Dilactose R) and 2.6 grams of croscarmellose sodium (AcDisol, product of Asahi Chemical Industry) were mixed for 2 minutes with a high-speed agitation granulator (FDG-C5, product of Fukae Industry), added with 0.65 gram of magnesium stearate and mixed for 10 seconds. The mixed powder was tableted with a single-shot tableting machine (KORSCH) to obtain a tablet (uncoated tablet) having a principal drug content of 11.5 mg/tablet, an average weight of 131.3 mg and a diameter of 7 mm.
  • KORSCH single-shot tableting machine
  • the obtained uncoated tablet was administered to beagle dogs and the change of the drug concentration in plasma was measured.
  • a suspension of loperamide hydrochloride was orally administered to four fasted beagle dogs at a rate of 0.12 mg/mL/kg together with 15 mL of ion-exchanged water and each dog was administered with two uncoated tablets each containing 11.5 mg of the drug after 30 minutes and allowed to drink 20 mL of ion-exchanged water.
  • Blood was collected at 0.5, 1, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours after the administration and the drug concentration in plasma was determined.
  • the pharmacokinetic parameters were determined by moment analysis using the plasma concentration data as a base. The results are shown in the Table 2.
  • the Tmax (time to reach Cmax) of the drug was 1 hour, the Cmax was 0.318 mg/L and the AUC( ⁇ ) was 1.29 mg.hr/L.
  • the mixed powder was tableted with a single-shot tableting machine to obtain a tablet of 7 mm diameter.
  • the produced tablet was coated with a coating liquid composed of 554.1 grams of purified water, 30.0 grams of hydroxypropylmethyl cellulose acetate succinate (AS-L-F type, product of Shin-Etsu Chemical Co., Ltd.), 6.0 grams of triethyl citrate (citroflex 2, SC-60), 9.0 grams of talc (product of Matsumura Sangyo Co.) and 0.9 gram of sodium laurylsulfate (product of Nikko Chemical Co.) by a coating machine (HCT-MINI, product of Freund Industrial Co.) to obtain an enteric coating tablet constituting the Example 2.
  • the charged amount of the uncoated tablet was 250 grams and the heater temperature was set to 60°C.
  • the content of the compound (A) in the obtained enteric coating tablet was 11.5 mg/tablet.
  • the effect of the enteric coating was confirmed by the following dissolution test.
  • the tablets were put into 900 mL of the first fluid of the Japanese Pharmacopeia (pH 1.2), a buffer solution of pH 6.0 and the second fluid of the Japanese Pharmacopeia (pH 6.8) one for each fluid and the dissolution of the compound (A) was measured at 37°C and 50 rpm.
  • the dissolution of the compound (A) was unobservable in the first fluid of the Japanese Pharmacopeia even after 5 hours.
  • the dissolution ratio of the compound (A) was about 20% after 15 minutes and about 100% after 30 minutes.
  • the dissolution ratio of the compound (A) was about 70% after 15 minutes and about 100% after 30 minutes.
  • the enteric tablet obtained by the above Example 2 and quickly dissolving at pH 6 or above was administered to beagle dogs and the change of the drug concentration in plasma was measured.
  • a suspension of loperamide hydrochloride was orally administered to four fasted beagle dogs at a rate of 0.12 mg/mL/kg together with 15 mL of ion-exchanged water and each dog was administered with two enteric tablets each containing 11.5 mg of the drug after 30 minutes and allowed to drink 20 mL of ion-exchanged water.
  • Blood was collected at 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours after the administration and the drug concentration in plasma was determined.
  • the pharmacokinetic parameters were determined by moment analysis using the data as a base. The results are shown in the Table 2.
  • the Tmax of the drug was 1 hour, the Cmax was 0.341 mg/L and the AUC( ⁇ ) was 1.38 mg.hr/L.
  • the AUC was increased and the retention time of the estimated effective blood concentration was prolonged compared with the Comparative Example 2.
  • Table 2 PK Parameter AUC mg.hr/L Cmax mg/L Tmax hr Comparative Example 2 1.29 0.318 1.0
  • Example 2 1.38 0.341 1.0
  • Example 2 Compound A tablet (enteric coating, quick releasing)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (4)

  1. Medizinische Zusammensetzung, enthaltend eine oder mehrere Verbindungen, ausgewählt aus der Gruppe, bestehend aus Verbindungen, dargestellt durch die Formel (I), Salzen dieser Verbindungen, Solvaten dieser Verbindungen und Solvaten dieser Salze, und wobei die medizinische Zusammensetzung mit einem enteralen Polymer beschichtet ist, das gegen eine Auflösung unter pH 4,5 beständig ist und bei pH 4,5 oder darüber löslich ist und dazu fähig ist, den Kontakt der Verbindungen mit Komponenten in Galle oder Bauchspeichel zu verringern, wobei das enterale Polymer eine oder mehrere Arten, ausgewählt aus der Gruppe, bestehend aus Hydroxypropylmethylzelluloseacetatsuccinat, Hydroxypropylmethylzellulosephthalat, Carboxymethylethylzellulose, Zelluloseacetatphthalat, Zelluloseacetattrimellitat, Polyvinylacetatphthalat und Methacrylsäurecopolymer, ist,
    Figure imgb0021
     wobei
    R1 ein Wasserstoffatom, ein Fluoratom, ein Chloratom, ein Bromatom, eine Hydroxylgruppe, eine Aminogruppe, eine Nitrogruppe, eine C1-C8 Alkylgruppe oder eine C1-C8 Alkoxygruppe ist,
    L eine direkte Bindung oder eine C1-C4 Alkylengruppe ist,
    R2 ein Fluoratom, ein Chloratom, ein Bromatom, eine Hydroxylgruppe, eine Aminogruppe, eine C1-C8 Alkoxygruppe, eine Carboxylgruppe, eine C1-C8 Alkoxycarbonylgruppe, eine Aryloxycarbonylgruppe, eine Aralkoxycarbonylgruppe, eine Carbamoylgruppe, wobei das die Carbamoylgruppe konstituierende Stickstoffatom mit einer Mono- oder Di-C1-C8 Alkylgruppe substituiert sein kann oder das Stickstoffatom einer Aminosäure sein kann, eine C1-C8 Alkylcarbonylgruppe, eine C1-C8 Alkylsulfenylgruppe, eine C1-C8 Alkylsulfinylgruppe, eine C1-C8 Alkylsulfonylgruppe, eine Mono- oder Di-C1-C8 Alkylaminogruppe, eine Mono- oder Di-C1-C8 Alkylaminosulfonylgruppe, eine Sulfogruppe, eine Phosphonogruppe, eine Bis(hydroxycarbonyl)methylgruppe, eine Bis(alkoxycarbonyl)methylgruppe oder eine 5-Tetrazolylgruppe ist,
    R3 ein Wasserstoffatom, ein Fluoratom, ein Chloratom, ein Bromatom, eine Hydroxylgruppe, eine Aminogruppe, eine Nitrogruppe, eine C1-C8 Alkylgruppe, eine C1-C8 Alkoxygruppe, eine Carboxylgruppe oder eine C1-C8 Alkoxycarbonylgruppe ist,
    X eine Gruppe der Formeln -O-, -S-, -SO-, -SO2-, -NH-CO-NH-, -N(R4)-, -CO-N(R6)-, -N(R5)-CO-, -N(R5)-SO2- oder -SO2-N(R5)- ist,
    wobei R4 ein Wasserstoffatom, eine C1-C10 Alkylgruppe, eine C1-C10 Alkylcarbonylgruppe, eine C1-C10 Alkylsulfonylgruppe, eine C3-C8 Cycloalkylgruppe oder eine Arylgruppe ist,
    R5 ein Wasserstoffatom, eine C1-C10 Alkylgruppe, eine C3-C8 Cycloalkylgruppe oder eine Arylgruppe ist, und wobei die Alkylgruppen von R4 und R5 mit einer Arylgruppe, einer Hydroxylgruppe, einer Aminogruppe, einem Halogenatom, einer C1-C8 Alkoxygruppe, einer Carboxylgruppe, einer C1-C8 Alkoxycarbonylgruppe, einer Aryloxycarbonylgruppe, einer Aralkoxycarbonylgruppe, einer Carbamoylgruppe oder einer 5-Tetrazolylgruppe substituiert sein können,
    Y eine fünf- bis achtgliedrige Ringgruppe der folgenden Formel 1-1 ist,
    Figure imgb0022
     wobei die Methylengruppe jedes Ringssystems durch eine Carbonylgruppe ersetzt sein kann und eine ungesättigte Bindung in dem Ring vorliegen kann, R6 ein Wasserstoffatom, ein Fluoratom, ein Chloratom, ein Bromatom, eine Hydroxylgruppe, eine Aminogruppe, eine Nitrogruppe, eine C1-C8 Alkylgruppe oder eine C1-C8 Alkoxygruppe ist,
    W C-H ist,
    Z ein Wasserstoffatom, eine C1-C10 Alkylgruppe (wobei die Alkylgruppe mit einer Hydroxylgruppe (ausschließlich des Falls einer C1 Alkylgruppe), einer Aminogruppe, einer C1-C8 Alkoxygruppe (ausschließlich des Falls einer C1 Alkylgruppe), einer Carboxylgruppe, einer C1-C8 Alkoxycarbonylgruppe, einer Aryloxycarbonylgruppe oder einer Aralkoxycarbonylgruppe substituiert sein kann), eine C1-C8 Alkylcarbonylgruppe, eine Arylcarbonylgruppe, eine Aralkylcarbonylgruppe, eine Amidinogruppe oder eine Gruppe der folgenden Formel 1-3 ist,
    Figure imgb0023
     wobei R7 eine C1-C8 Alkylgruppe (wobei die Alkylgruppe mit einer Hydroxylgruppe oder einer C1-C8 Alkoxygruppe substituiert sein kann), eine Aralkylgruppe oder eine Arylgruppe ist,
    m eine ganze Zahl von 1 bis 3 ist und
    n eine ganze Zahl von 0 bis 3 ist.
  2. Medizinische Zusammensetzung nach Anspruch 1, wobei die Verbindungen nicht freigesetzt werden, bis die medizinische Zusammensetzung den Zwölffingerdarm, den folgenden Dünndarm oder Dickdarm erreicht.
  3. Medizinische Zusammensetzung nach Anspruch 1 oder 2, wobei die medizinische Zusammensetzung zusätzlich ein Abbaumittel enthält und ganz oder teilweise mit einer wasserunlöslichen und wasserpermeablen Substanz beschichtet ist, und wobei die beschichtete Zusammensetzung eine Mechanismus aufweist, die beschichtete Zusammensetzung nach Kontakt mit Wasser für 0,5 bis 4,5 Stunden zu zerstören oder zu öffnen.
  4. Medizinische Zusammensetzung nach Anspruch 1 oder 2, wobei die Verbindung mit einem Material beschichtet ist, das durch enterale Bakterien zersetzbar ist, die im unteren Teil des Dünndarms und bis zum/im Dickdarm angesiedelt sind,
EP00900919A 1999-01-28 2000-01-25 Freisetzungsregulierende zubereitungen Expired - Lifetime EP1179344B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP1981599 1999-01-28
JP1981599 1999-01-28
PCT/JP2000/000353 WO2000044380A1 (en) 1999-01-28 2000-01-25 Release-regulating preparations

Publications (3)

Publication Number Publication Date
EP1179344A1 EP1179344A1 (de) 2002-02-13
EP1179344A4 EP1179344A4 (de) 2004-05-06
EP1179344B1 true EP1179344B1 (de) 2006-09-13

Family

ID=12009831

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00900919A Expired - Lifetime EP1179344B1 (de) 1999-01-28 2000-01-25 Freisetzungsregulierende zubereitungen

Country Status (10)

Country Link
US (1) US6676968B1 (de)
EP (1) EP1179344B1 (de)
KR (1) KR20010101772A (de)
CN (1) CN1152684C (de)
AT (1) ATE339204T1 (de)
AU (1) AU773156B2 (de)
CA (1) CA2360686A1 (de)
DE (1) DE60030710D1 (de)
TW (1) TW592699B (de)
WO (1) WO2000044380A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060448A1 (fr) * 2001-01-30 2002-08-08 Teijin Limited Composition medicinale
AR035425A1 (es) * 2001-01-30 2004-05-26 Teijin Ltd Cristal de diclorhidrato del acido 3-(3-amidinofenil)-5-[({[1-(iminoetil)-4-piperidil]metil}amino)metil]benzoico y proceso para prepararlo
CN117467423B (zh) * 2023-12-28 2024-03-05 成都华阳兴华化工有限公司 耐高温泡沫驱油剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE59303178D1 (de) * 1992-04-28 1996-08-14 Thomae Gmbh Dr K Tritiumarkierte Fibrinogen-Rezeptor-Antagonisten, deren Verwendung und Verfahren zur ihrer Herstellung
JPH092977A (ja) * 1995-06-21 1997-01-07 Dai Ichi Seiyaku Co Ltd 経口投与用医薬組成物
JPH101467A (ja) 1996-06-13 1998-01-06 Banyu Pharmaceut Co Ltd ビフェニルアミジン誘導体
CN1226175A (zh) * 1996-07-23 1999-08-18 第一制药株式会社 吸收促进剂
JPH10231254A (ja) * 1996-12-19 1998-09-02 Dai Ichi Seiyaku Co Ltd 経口吸収改善医薬用組成物
JPH11152269A (ja) * 1997-11-20 1999-06-08 Teijin Ltd ビフェニルアミジン誘導体
UA52797C2 (uk) 1997-11-20 2003-01-15 Тейдзін Лімітед Похідне біфеніламідину, проліки, інгібітор коагуляції крові, агент для профілактики тромбозу або емболії та агент для терапії тромбозу або емболії
KR20010032175A (ko) 1997-11-20 2001-04-16 야스이 쇼사꾸 비페닐아미딘 유도체
US5886239A (en) * 1997-11-21 1999-03-23 Baxter International Inc. Method of preparing monofluoromethyl ethers
DE19819548A1 (de) * 1998-04-30 1999-11-04 Merck Patent Gmbh Biphenylderivate
JP2000178243A (ja) * 1998-12-14 2000-06-27 Teijin Ltd ビフェニルアミジン誘導体

Also Published As

Publication number Publication date
KR20010101772A (ko) 2001-11-14
DE60030710D1 (de) 2006-10-26
TW592699B (en) 2004-06-21
EP1179344A4 (de) 2004-05-06
CN1152684C (zh) 2004-06-09
AU773156B2 (en) 2004-05-20
EP1179344A1 (de) 2002-02-13
CN1338935A (zh) 2002-03-06
WO2000044380A1 (en) 2000-08-03
ATE339204T1 (de) 2006-10-15
CA2360686A1 (en) 2000-08-03
AU3078300A (en) 2000-08-18
US6676968B1 (en) 2004-01-13

Similar Documents

Publication Publication Date Title
KR101921288B1 (ko) 옵신 결합 리간드, 조성물 및 사용 방법
CA3179890A1 (en) Salt and crystal forms of glp-1r agonists and uses thereof
AU2001275326B2 (en) Treatment of gastroesophageal reflux disease using piperidine derivatives
MXPA02009312A (es) Inhibidores de las metaloproteasas que contienen cadenas laterales heterociclicas.
TW200845981A (en) Compounds and compositions as channel activating protease inhibitors
AU2001275326A1 (en) Treatment of gastroesophageal reflux disease using piperidine derivatives
EP2749554B1 (de) 2,5-disubstituierte Arylsulfonamid-CCR3-Antagonisten
WO1999026918A1 (en) Biphenylamidine derivatives
AU2010239337B2 (en) 2,5-disubstituted arylsulfonamide CCR3 antagonists
JP2003528080A (ja) 複素環式側鎖を含有するｎ−置換型メタロプロテアーゼ阻害物質
EP1179344B1 (de) Freisetzungsregulierende zubereitungen
US20100063583A1 (en) Use of soluble epoxide hydrolase inhibitors in the treatment of inflammatory vascular diseases
CN103626825A (zh) 靶向肝脏的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
EP1973875B1 (de) Verbindungen und verfahren zur inhibierung der wechselwirkung von bcl-proteinen mit bindungspartnern
ES2627841T3 (es) Derivados heterocíclicos que contienen grupos amino primarios y diazeniodiolatos
JP3907029B2 (ja) 環状アミン誘導体を含有する医薬
EP0800516B1 (de) Fibrinogen receptor antagonisten mit substituierten b-aminosäurenestern und diese enthaltende pharmazeutische präparate
RU2272027C2 (ru) Производные 3-гидроксипиперидина и фармацевтическая композиция на их основе
JPWO2000044380A1 (ja) 放出制御製剤
TW403745B (en) Novel substituted -amidinobenzene derivative and pharmaceutical compositions thereof
AU2006201053B2 (en) Materials and methods for the treatment of gastroesophageal reflux disease
EP0424901A1 (de) Dihydropyridin-Derivate und pharmazeutische Zusammensetzungen
HK40092212A (zh) 作为glp-1受体激动剂的化合物及其用途
HK40092212B (zh) 作为glp-1受体激动剂的化合物及其用途
LT3681B (en) N-acyl-alpha-amino acid derivatives, method for producting thereof,pharmaceutical compositions and preparing them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040318

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 9/62 B

Ipc: 7A 61K 9/58 B

Ipc: 7A 61K 47/38 B

Ipc: 7A 61K 31/445 A

Ipc: 7A 61K 9/32 B

Ipc: 7A 61P 43/00 B

Ipc: 7A 61K 31/216 B

Ipc: 7C 07D 211/62 B

Ipc: 7A 61P 1/00 B

Ipc: 7A 61K 31/192 B

Ipc: 7A 61K 31/155 B

Ipc: 7A 61K 47/30 B

Ipc: 7A 61K 9/36 B

17Q First examination report despatched

Effective date: 20050301

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/00 20060101ALI20060208BHEP

Ipc: A61K 31/192 20060101ALI20060208BHEP

Ipc: A61K 31/155 20060101ALI20060208BHEP

Ipc: A61K 9/62 20060101ALI20060208BHEP

Ipc: A61P 43/00 20060101ALI20060208BHEP

Ipc: A61K 9/36 20060101ALI20060208BHEP

Ipc: A61K 47/38 20060101ALI20060208BHEP

Ipc: A61K 9/32 20060101ALI20060208BHEP

Ipc: A61K 31/216 20060101ALI20060208BHEP

Ipc: A61K 47/30 20060101ALI20060208BHEP

Ipc: A61K 31/445 20060101AFI20060208BHEP

Ipc: A61K 9/58 20060101ALI20060208BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20060913

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60030710

Country of ref document: DE

Date of ref document: 20061026

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061213

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061224

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070131

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070302

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EN Fr: translation not filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20070614

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20070125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070125

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061214

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070518

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070125

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060913